A novel nanoparticle formulation for sustained paclitaxel delivery

AAPS PharmSciTech

Volumn 9, Issue 2, 2008, Pages 486-493

  Trickler, W J ^a   Nagvekar, A A ^a   Dash, A K ^a  

^a CREIGHTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Cancer; Chitosan; GMO; MDA MB 231; Mucoadhesive; Nanoparticles; Paclitaxel

Indexed keywords

CHITOSAN; GLYCEROL OLEATE; NANOPARTICLE; PACLITAXEL; POLYCATION; SOLVENT; ACYLGLYCEROL; ANTINEOPLASTIC AGENT; DRUG CARRIER;

ARTICLE; BREAST CANCER; CANCER CELL; CELL ADHESION; CELL ASSAY; CONTROLLED STUDY; CYTOTOXICITY; DRUG COATING; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG RELEASE; DRUG SAFETY; DRUG UPTAKE; EMULSION; ENCAPSULATION; FREEZE DRYING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HYDROPHILICITY; HYDROPHOBICITY; IC 50; IN VITRO STUDY; PARTICLE SIZE; POWDER; SURFACE CHARGE; SUSPENSION; SUSTAINED RELEASE FORMULATION; TRANSMISSION ELECTRON MICROSCOPY; BREAST TUMOR; CELL MEMBRANE PERMEABILITY; CELL SURVIVAL; CHEMISTRY; DELAYED RELEASE FORMULATION; DOSE RESPONSE; DRUG FORMULATION; FEMALE; KINETICS; METABOLISM; METHODOLOGY; PATHOLOGY; PHARMACEUTICS; SOLUBILITY; SURFACE PROPERTY; TIME; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MEMBRANE PERMEABILITY; CELL SURVIVAL; CHEMISTRY, PHARMACEUTICAL; CHITOSAN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG CARRIERS; DRUG COMPOUNDING; EMULSIONS; FEMALE; GLYCERIDES; HUMANS; INHIBITORY CONCENTRATION 50; KINETICS; MICROSCOPY, ELECTRON, TRANSMISSION; NANOPARTICLES; PACLITAXEL; PARTICLE SIZE; SOLUBILITY; SURFACE PROPERTIES; TECHNOLOGY, PHARMACEUTICAL; TIME FACTORS;

EID: 51449104994     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/s12249-008-9063-7     Document Type: Article

References (42)

1. J. A. Ajani, et al. Phase II study of Taxol in patients with advanced gastric carcinoma. Cancer J. Sci. Am. 4 (4):269-274 (1998).
2. B. B. Rogers. Taxol: A promising new drug of the '90s. Oncol. Nurs. Forum 20 (10):1483-1489 (1993).
3. A. K. Singla, et al. Paclitaxel and its formulations. Int. J. Pharm. 235 (1-2):179-192 (2002).
4. B. D. Tarr, and S. H. Yalkowsky. A new parenteral vehicle for the administration of some poorly soluble anti-cancer drugs. J. Parenter. Sci. Technol. 41: 31-33 (1987).
5. T. C. Chao, et al. Paclitaxel in a novel formulation containing less Cremophor EL as first-line therapy for advanced breast cancer: A phase II trial. Invest. New Drugs 23 (2):171-177 (2005).
6. H. Gelderblom, et al. Cremophor EL: The drawbacks and advantages of vehicle selection for drug formulation. Eur. J. Cancer 37 (13):1590-1598 (2001).
7. D. Friedland, et al. Hypersensitivity reactions from taxol and etoposide. J. Natl. Cancer Inst. 85 (24):2036 (1993).
8. N. K. Ibrahim, et al. Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin. Cancer Res. 8 (5):1038-1044 (2002).
9. W. J. Gradishar. Albumin-bound paclitaxel: A next-generation taxane. Expert Opin. Pharmacother. 7 (8):1041-1053 (2006).
10. M. Socinski. Update on nanoparticle albumin-bound paclitaxel. Clin. Adv. Hematol. Oncol. 4 (10):745-746 (2006).
11. J. Lee Villano, et al. Abraxane induced life-threatening toxicities with metastatic breast cancer and hepatic insufficiency. Invest. New Drugs 24 (5):455-456 (2006).
12. A. Bernkop-Schnurch, et al. Thiomers: Preparation and in vitro evaluation of a mucoadhesive nanoparticulate drug delivery system. Int. J. Pharm. 317 (1):76-81 (2006).
13. F. Zheng, et al. Chitosan nanoparticle as gene therapy vector via gastrointestinal mucosa administration: Results of an in vitro and in vivo study. Life Sci. 80 (4):388-396 (2007).
14. A. M. De Campos, et al. Chitosan nanoparticles: A new vehicle for the improvement of the delivery of drugs to the ocular surface. Application to cyclosporin A. Int. J. Pharm. 224 (1-2):159-168 (2001).
15. G. Sandri, et al. Nanoparticles based on N -trimethylchitosan: evaluation of absorption properties using in vitro (Caco-2 cells) and ex vivo (excised rat jejunum) models. Eur. J. Pharm. Biopharm. 65 (1):68-77 (2007).
16. A. Moore, et al. In vivo targeting of underglycosylated MUC-1 tumor antigen using a multimodal imaging probe. Cancer Res. 64 (5):1821-1827 (2004).
17. F. Cui, et al. Preparation and characterization of mucoadhesive polymer-coated nanoparticles. Int. J. Pharm. 316 (1-2):154-161 (2006).
18. K. A. Howard, et al. RNA interference in vitro and in vivo using a novel chitosan/siRNA nanoparticle system. Mol. Ther. 14 (4):476-484 (2006).
19. H. Takeuchi, et al. Enteral absorption of insulin in rats from mucoadhesive chitosan-coated liposomes. Pharm. Res. 13 (6):896-901 (1996).
20. H. Takeuchi, et al. Novel mucoadhesion tests for polymers and polymer-coated particles to design optimal mucoadhesive drug delivery systems. Adv. Drug Deliv. Rev. 57 (11):1583-1594 (2005).
21. J. Thongborisute, et al. The effect of particle structure of chitosan-coated liposomes and type of chitosan on oral delivery of calcitonin. J. Drug Target 14 (3):147-154 (2006).
22. S. Jauhari, and A. K. Dash. A mucoadhesive in situ gel delivery system for paclitaxel. AAPS PharmSciTech. 7 (2):E53 (2006).
23. J. Panyam, and V. Labhasetwar. Targeting intracellular targets. Curr. Drug Deliv. 1 (3):235-247 (2004).
24. A. K. Dash, et al. X-ray powder diffractometric method for quantitation of crystalline drug in microparticulate systems. I. Microspheres. J. Pharm. Sci. 91 (4):83-990 (2002).
25. Y. Wu, et al. Chitosan nanoparticles as a novel delivery system for ammonium glycyrrhizinate. Int. J. Pharm. 295 (1-2):235-245 (2005).
26. F. Q. Hu, et al. Shell cross-linked stearic acid grafted chitosan oligosaccharide self-aggregated micelles for controlled release of paclitaxel. Colloids Surf. B Biointerfaces 50 (2):97-103 (2006).
27. J. Hyung Park, et al. Self-assembled nanoparticles based on glycol chitosan bearing hydrophobic moieties as carriers for doxorubicin: In vivo biodistribution and anti-tumor activity. Biomaterials 27 (1):119-126 (2006).
28. J. H. Kim, et al. Hydrophobically modified glycol chitosan nanoparticles as carriers for paclitaxel. J. Control Release 111 (1-2):228-234 (2006).
29. F. Maestrelli, et al. A new drug nanocarrier consisting of chitosan and hydoxypropylcyclodextrin. Eur. J. Pharm. Biopharm. 63 (2):79-86 (2006).
30. S. A. Agnihotri, et al. Recent advances on chitosan-based micro- and nanoparticles in drug delivery. J. Control Release 100 (1):5-28 (2004).
31. C. Prego, et al. Chitosan-PEG nanocapsules as new carriers for oral peptide delivery. Effect of chitosan pegylation degree. J. Control Release 111 (3):299-308 (2006).
32. M. Garcia-Fuentes, et al. A comparative study of the potential of solid triglyceride nanostructures coated with chitosan or poly(ethylene glycol) as carriers for oral calcitonin delivery. Eur. J. Pharm. Sci. 25 (1):133-143 (2005).
33. E. S. Lutton. Phase behavior of aqueous systems of monoglycerides. J. Am. Oil Chem. Soc. 42 (12):1068-1070 (1965).
34. G. Garg, and S. Saraf. Cubosomes: An overview. Biol. Pharm. Bull. 30 (2):350-353 (2007).
35. S. Ganguly, and A. K. Dash. A novel in situ gel for sustained drug delivery and targeting. Int. J. Pharm. 276 (1-2):83-92 (2004).
36. Y. Sadhale, and J. C. Shah. Glyceryl monooleate cubic phase gel as chemical stability enhancer of cefazolin and cefuroxime. Pharm. Dev. Technol. 3 (4):549-556 (1998).
37. M. Uner. Preparation, characterization and physico-chemical properties of solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC): Their benefits as colloidal drug carrier systems. Pharmazie 61 (5):375-386 (2006).
38. P. M. Bummer. Physical chemical considerations of lipid-based oral drug delivery-solid lipid nanoparticles. Crit. Rev. Ther. Drug Carrier Syst. 21) (1):1-20 (2004).
39. P. R. Lockman, et al. Nanoparticle technology for drug delivery across the blood-brain barrier. Drug Dev. Ind. Pharm. 28 (1):1-13 (2002).
40. S. J. Douglas, et al. Nanoparticles in drug delivery. Crit. Rev. Ther. Drug Carrier Syst. 3 (3):233-261 (1987).
41. H. Takeuchi, et al. Mucoadhesive nanoparticulate systems for peptide drug delivery. Adv. Drug Deliv. Rev. 47 (1):39-54 (2001).
42. F. Shikata, et al. In vitro cellular accumulation of gadolinium incorporated into chitosan nanoparticles designed for neutron-capture therapy of cancer. Eur. J. Pharm. Biopharm. 53 (1):57-63 (2002).